Updated Prior Authorization Criteria for Lisocabtagene Maraleucel (Breyanzi)
Customize your policy alerts
Sign up for all parklandcommunityhealthplan policy alerts
Know when parklandcommunityhealthplan releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs Texas Medicaid prior authorization and reimbursement requirements for lisocabtagene maraleucel (Breyanzi) infusion therapy for adult Medicaid clients with relapsed or refractory mantle cell lymphoma or marginal zone lymphoma. The updated criteria apply to dates of service on or after December 1, 2026.
Texas Medicaid is updating prior authorization criteria for lisocabtagene maraleucel (Breyanzi) procedure code Q2054 effective December 1, 2026.
Coverage Criteria
Initial Breyanzi authorization criteria
Prior authorization may be approved when the adult client meets one of the following diagnosis criteria.
Qualifying lymphoma pathway
- Mantle cell lymphoma pathway: The client has relapsed or refractory mantle cell lymphoma and has received at least two prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor.At least 2 prior systemic therapy lines; must include a BTK inhibitor
Marginal zone lymphoma pathways
- Prior-therapy pathway: The client received at least two prior lines of systemic therapy, including an anti-CD20 antibody and an alkylating agent.At least 2 prior systemic therapy lines; must include an anti-CD20 antibody and alkylating agent
- Post-HSCT relapse pathway: The client has relapsed after hematopoietic stem cell transplantation.Relapse after HSCT
Initial Therapy Criteria
Initial Breyanzi therapy
Prior authorization may be approved when the adult client meets one of the following diagnosis criteria.
Initial authorization pathways
- Mantle cell lymphoma: The client has relapsed or refractory mantle cell lymphoma and has received at least two prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor.At least 2 prior lines; include a BTK inhibitor
Marginal zone lymphoma
- Prior-therapy pathway: The client received at least two prior lines of systemic therapy, including an anti-CD20 antibody and an alkylating agent.At least 2 prior lines; include an anti-CD20 antibody and alkylating agent
- Post-HSCT relapse pathway: The client has relapsed after hematopoietic stem cell transplantation.Relapse after HSCT
Procedure and Diagnosis Coding
| Q2054 | lisocabtagene maraleucel (Breyanzi) |
| C8840 | additional diagnosis code |
Provider Actions
Obtain prior authorization before Breyanzi infusion
Prior authorization is required for lisocabtagene maraleucel (Breyanzi) infusion therapy. Approval may be granted for an adult client with relapsed or refractory mantle cell lymphoma who has received at least two prior lines of systemic therapy, including a BTK inhibitor, or for relapsed or refractory marginal zone lymphoma meeting either specified prior-therapy pathway or post-HSCT relapse pathway.
- Mantle cell lymphoma: at least two prior systemic therapy lines, including a Bruton tyrosine kinase inhibitor.
- Marginal zone lymphoma: at least two prior systemic therapy lines, including an anti-CD20 antibody and alkylating agent, or relapse after hematopoietic stem cell transplantation.
Document diagnosis and treatment history
Submit documentation supporting the diagnosis of relapsed or refractory mantle cell lymphoma or marginal zone lymphoma and the applicable treatment history. Include the required prior therapies and agents, or documentation of relapse after hematopoietic stem cell transplantation, as applicable.
- Mantle cell lymphoma: document at least two prior lines of systemic therapy, including a BTK inhibitor.
- Marginal zone lymphoma: document at least two prior lines including an anti-CD20 antibody and alkylating agent, or relapse after HSCT.
Prevent denial by confirming qualifying history
Prior authorization may be denied when the client does not meet a complete lymphoma-specific qualifying pathway. This includes insufficient prior therapy for mantle cell lymphoma or failure to meet either the required prior-therapy pathway or the post-HSCT relapse pathway for marginal zone lymphoma.
- Mantle cell lymphoma: denial risk applies if the client has not received at least two prior lines of systemic therapy, including a BTK inhibitor.
- Marginal zone lymphoma: the client must have at least two prior systemic therapy lines including an anti-CD20 antibody and alkylating agent, or documented relapse after HSCT.
Therapy Background
Lisocabtagene maraleucel (Breyanzi) is an FDA-approved cellular immunotherapy for adult clients with relapsed or refractory marginal zone lymphoma who have received at least two prior lines of systemic therapy. This policy also establishes prior authorization criteria for adult clients with relapsed or refractory mantle cell lymphoma, including prior treatment with a Bruton tyrosine kinase inhibitor. The updated requirements apply to Texas Medicaid dates of service on or after December 1, 2026.
Key Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.